Immunology Market (By Drug Class: Monoclonal Antibodies, Fusion Proteins, Immunosuppressants, others; By Disease Indication: Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis Of Organ Rejection; By Distribution Channel: Hospital Pharmacie, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Immunology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Immunology Market, by Drug Class, 2024-2033
8.1.1 Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Fusion Proteins
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Immunosuppressants
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2033)
9.1. Immunology Market, by Disease Indication, 2024-2033
9.1.1. Rheumatoid Arthritis
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Psoriatic Arthritis
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Plaque Psoriasis
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Ankylosing Spondylitis
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Inflammatory Bowel Disease
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Prophylaxis Of Organ Rejection
9.1.6.1. Market Revenue and Forecast (2021-2033)
10.1. Immunology Market, by Distribution Channel, 2024-2033
10.1.1. Hospital Pharmacie
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Disease Indication (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2033)
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Janssen Global Services, LLC (Johnson & Johnson)
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. ALLERGAN.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Amgen Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Other Prominent Players.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck Sharp & Dohme Corp.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample